A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

November 3, 2025

Primary Completion Date

December 27, 2027

Study Completion Date

October 29, 2029

Conditions

Palmoplantar Pustulosis

Interventions

DRUG

Bimekizumab

Study participants will receive bimekizumab at pre-specified time points.

DRUG

Placebo

Study participants will receive matching placebo at pre-specified time points.

All Listed Sponsors

lead

UCB Biopharma SRL

INDUSTRY